Androgen deprivation therapy (ADT) is a standard treatment for prostate cancer. It lowers testosterone to slow cancer. Testosterone also supports bone density and muscle mass. When ADT suppresses it, bone can weaken quickly – sometimes within the first few months. Researchers have tested two approaches to counter this: vitamin D and calcium, and structured resistance exercise. This article covers what trials show, what doses work, and what to discuss with your oncology team.
Why ADT Is Hard on Bone
Bone is constantly broken down and rebuilt. This process depends on hormones, including testosterone. When ADT lowers testosterone, cells that break bone down work faster than cells that rebuild it. Research on bone loss during ADT found that hip and spine bone mineral density (BMD) can drop 2 to 8 percent in the first year of treatment. Expert consensus on bone loss from prostate cancer treatment found that long-term ADT is linked to up to 10 percent BMD loss over two years – and 1.5 to 2.0 times higher fracture risk compared with untreated men. Hip and spine fractures can interrupt cancer treatment, reduce mobility, and increase dependence on others. That is why oncology guidelines recommend bone health checks at the start of ADT, not after a fracture occurs.
Comparing Vitamin D Approaches During ADT
Most guidelines recommend calcium and vitamin D supplements for all men on ADT. Researchers are also testing whether higher vitamin D doses offer more bone protection than standard doses. The table below compares the two approaches on five key factors.
| Factor | Standard-Dose Vitamin D and Calcium | High-Dose Vitamin D |
|---|---|---|
| Typical daily dose studied | 800 to 2,000 IU vitamin D; 1,200 to 1,500 mg total calcium from diet and supplements | Doses above 2,000 IU under active study; 4,000 IU per day studied for one year in prostate cancer patients with no adverse effects or disease progression in one review |
| Evidence grade | Expert consensus; adopted in multiple international oncology guidelines | Phase 2 randomized controlled trial only |
| Bone outcome reported | 1,200 mg calcium with vitamin D cut all-fracture risk by roughly 20 percent in adults age 50 and older; lower doses of 500 to 1,000 mg calcium and 200 to 500 IU vitamin D were not enough to stop BMD loss in a review of 12 trials | Significantly reduced hip and femoral neck BMD loss versus control group; benefit strongest in men with low baseline vitamin D |
| Monitoring required | Baseline 25-OH vitamin D blood test recommended; routine follow-up | Regular blood tests essential; elevated blood calcium is a possible risk at higher doses |
| Who may benefit most | All men starting ADT, regardless of baseline vitamin D level | Men with low baseline serum 25-OH vitamin D, based on Phase 2 subgroup findings |
Table sources: Calcium and Vitamin D Supplementation During ADT – critical review (PMC3448410); High-dose vitamin D to reduce bone loss during ADT – Phase 2 RCT (PMC11214601); Lifestyle guidelines for managing ADT side effects – update (PMC5508230).
What the Evidence Shows on Vitamin D and Calcium
A critical review of calcium and vitamin D supplements during ADT (PMC3448410) found that guidelines recommend 1,200 to 1,500 mg of total daily calcium from all sources – food and supplements combined – plus 800 to 2,000 IU of vitamin D per day for men on ADT. The review found that getting at least 1,200 mg of calcium daily with vitamin D cuts all-fracture risk by roughly 20 percent for adults age 50 and older. The same review looked at 12 clinical trials and found that lower doses – 500 to 1,000 mg of calcium and 200 to 500 IU of vitamin D daily – were not enough to stop BMD loss in men on ADT. This finding supports the shift toward the higher doses now recommended by most oncology guidelines.
The review also noted that 4,000 IU of vitamin D daily for one year in prostate cancer patients did not seem to raise adverse effects or disease progression in the studies reviewed. This is not a blanket endorsement of 4,000 IU. It is a finding from a review of current data, not a large phase III trial. Any dose above the standard guideline range should only be taken under medical supervision, with regular blood tests for vitamin D and calcium levels.
A Phase 2 randomized controlled trial (PMC11214601) tested whether high-dose vitamin D could protect bone during ADT better than standard doses. The trial found that high-dose vitamin D significantly reduced hip and femoral neck BMD loss compared with a control group. The benefit was strongest in men who had low baseline serum 25-hydroxyvitamin D at the start of ADT.
This shows why checking a 25-OH vitamin D blood test before or at the start of ADT is useful. Research on vitamin D deficiency in prostate cancer (PMC12198872) found that deficiency is common in this group even in sunny climates, and that ADT may make it worse. A low starting level may mean that standard doses are not enough to maintain adequate vitamin D during treatment.
Calcium from food – dairy products, fortified plant-based milks, white beans, canned fish with bones, and leafy greens – counts toward the daily target. Supplemental calcium fills the gap when diet falls short. The right amount depends on how much a person gets from food. A registered dietitian can help calculate that gap and advise on the safest form of supplement for your situation.
Resistance Training: What the Trials Show
Muscle and bone are connected. When muscles contract, they pull on bone. That pull is a signal that tells bone to stay dense. When ADT reduces muscle mass, that signal weakens. Resistance training applies load to muscles and bone, partly replacing the signal that falling testosterone removes.
A randomized controlled trial (PMC4433162) found that resistance training significantly reduced disability in prostate cancer survivors on ADT. Researchers reported that resistance exercise can offset the ADT-related loss of lean body mass and weakness that many men experience during treatment. Both changes – less lean mass and weaker muscles – increase fall risk and fracture risk.
A Phase III clinical trial of exercise types in men with prostate cancer (PMC2713263) compared different types of exercise and found that resistance training produced consistent benefit for keeping physical function during treatment. Separate research found that combining impact-loading exercises with resistance training may help bone density at the spine and hip most – the two sites most affected by ADT-related bone loss.
What a Resistance Programme During ADT May Look Like
The following reflects what has been studied in clinical trials. It is not a personalized exercise plan. Any exercise programme during active cancer treatment should be discussed with your oncology team, and men with bone metastases require modified routines designed by a physiotherapist or exercise specialist with cancer experience.
- Frequency: most trials in this group studied 2 to 3 supervised sessions per week.
- Type of exercise: movements that load major muscle groups – legs, hips, back, and shoulders – using resistance machines, free weights, or body weight.
- Progression: load and volume are generally increased slowly over weeks, guided by individual tolerance and response.
- Safety note: always confirm with your oncologist before starting or increasing weight-bearing exercise, especially if bone metastases are present or suspected.
A pilot randomized controlled trial (PMC5726104) studied a structured resistance training programme with protein supplementation in prostate cancer survivors on ADT. The combination was feasible and preserved lean mass. The role of dietary protein with resistance training is a practical detail worth raising with a dietitian or your oncology team when planning a programme.
DEXA Scanning: Tracking Bone Over Time
A DEXA scan is a low-dose imaging test that measures BMD at the hip and spine. It is the standard tool for diagnosing osteoporosis and tracking bone changes over time. A comprehensive bone-health management guide for men on ADT recommended a baseline DEXA scan before or shortly after starting ADT, followed by yearly testing while treatment continues. DEXA results, combined with a fracture-risk assessment tool like FRAX, help a care team decide whether lifestyle changes alone are enough or whether prescription bone-protective drugs – such as bisphosphonates or denosumab – are also needed. If you are on ADT and have not had a baseline DEXA scan yet, ask about it at your next oncology appointment.
Putting It Together: A Practical Approach
Vitamin D, calcium, and resistance training are among the most studied lifestyle strategies for bone protection during ADT. They work together – not as alternatives to each other – and they are part of a broader care plan that also includes limiting alcohol, quitting smoking, managing fall risks at home, and, when DEXA results indicate it, prescription bone-protective medication. Some men on ADT raise concerns about bone pain with their teams. If you are researching evidence-based options for pain management that work with hormonal therapies, the article on low-dose naltrexone for cancer pain: dosing, evidence, and safety with chemotherapy and hormonal therapies reviews what current data show on that approach.
When comparing vitamin D formulations or calcium supplement options during ADT, look at the dose per serving and the type of vitamin D. D3 (cholecalciferol) is the most commonly studied form. Oncostore’s Nutraceuticals category lists vitamin D and bone-support supplements available, which may help when preparing questions for your oncologist or pharmacist about what is right for your dose and treatment stage.
If you are taking prescription medications – including ADT drugs such as leuprolide, degarelix, enzalutamide, or abiraterone – or are already on bisphosphonates or denosumab, talk with your oncologist or pharmacist before adding or changing any supplement. Vitamin D at higher doses can raise blood calcium to unsafe levels in people with certain conditions, including granulomatous disease. People who are pregnant or breastfeeding should also speak with a clinician before taking vitamin D above standard dietary reference levels.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
